000			04025nam a22007097a 4500
008			190724s20192019 xxu||||| |||| 00| 0 eng d
022			_a0954-6111
024			_a10.1016/j.rmed.2019.05.012 [doi]
024			_aS0954-6111(19)30164-7 [pii]
040			_aOvid MEDLINE(R)
099			_a31176796
245			_aLong-term treatment with human immunoglobulin for antisynthetase syndrome-associated interstitial lung disease.
251			_aRespiratory Medicine. 154:6-11, 2019 Jul - Aug.
252			_aRespir Med. 154:6-11, 2019 Jul - Aug.
252			_zRespir Med. 154:6-11, 2019 Jul - Aug.
253			_aRespiratory medicine
260			_c2019
260			_fFY2020
265			_sppublish
266			_d2019-06-21
268			_aRespiratory Medicine. 154:6-11, 2019 Jul - Aug.
520			_aBACKGROUND: Interstitial lung disease-associated antisynthetase syndrome (AS-ILD) carries significant morbidity and mortality. Corticosteroids and immunosuppressive drugs are the mainstay of treatment. Human immunoglobulin (IVIg), an immunomodulator without immunosuppressive properties, is effective in myositis but the evidence supporting its use in ILD is scarce.
520			_aCONCLUSIONS: IVIg may be a useful complementary therapy in active progressive AS-ILD but is associated with potential side effects. Fssssurther investigation is required to determine the value of IVIg as an initial treatment in AS-ILD.
520			_aCopyright (c) 2019. Published by Elsevier Ltd.
520			_aMETHODS: Retrospective analysis of AS-ILD patients. Linear mixed models using restricted maximum likelihood estimation was used to estimate the change in lung function and corticosteroid dose over time.
520			_aOBJECTIVE: To describe clinical outcomes of AS-ILD patients receiving IVIg.
520			_aRESULTS: Data from 17 patients was analyzed. Median follow-up was 24.6 months. Fourteen patients had refractory disease. The mean percent-predicted forced vital capacity (FVC%) (p=0.048) and percent-predicted diffusing capacity of the lung for carbon monoxide (DLCO%) (p=0.0223) increased over time, while the mean prednisone dose (p<0.001) decreased over time. Seven patients achieved a >10% increase in FVC%, including two who used IVIg as initial treatment. Five patients showed a >10% increase in DLCO% and TLC%. Nine (53%) patients experienced side effects.
546			_aEnglish
650			_a*Immunoglobulins, Intravenous/tu [Therapeutic Use]
650			_a*Immunologic Factors/tu [Therapeutic Use]
650			_a*Lung Diseases, Interstitial/th [Therapy]
650			_a*Myositis/th [Therapy]
650			_aAdministration, Intravenous
650			_aAdrenal Cortex Hormones/tu [Therapeutic Use]
650			_aAdult
650			_aAged
650			_aCarbon Monoxide/me [Metabolism]
650			_aFemale
650			_aFollow-Up Studies
650			_aHumans
650			_aImmunoglobulins, Intravenous/ae [Adverse Effects]
650			_aImmunosuppressive Agents/tu [Therapeutic Use]
650			_aLung Diseases, Interstitial/co [Complications]
650			_aLung Diseases, Interstitial/mo [Mortality]
650			_aLung/pp [Physiopathology]
650			_aMale
650			_aMiddle Aged
650			_aMyositis/co [Complications]
650			_aMyositis/mo [Mortality]
650			_aPrednisone/tu [Therapeutic Use]
650			_aPulmonary Diffusing Capacity/de [Drug Effects]
650			_aRetrospective Studies
650			_aTreatment Outcome
650			_aVital Capacity/de [Drug Effects]
651			_aMedStar Washington Hospital Center
656			_aMedicine/Internal Medicine
657			_aJournal Article
700			_aHuapaya, Julio A
790			_aAlbayda J, Casal-Dominguez M, Christopher-Stine L, Danoff SK, Hallowell R, Huapaya JA, Hussien A, Johnson C, Lin CT, Mammen AL, Paik JJ, Pinal-Fernandez I, Silhan L
856			_uhttps://dx.doi.org/10.1016/j.rmed.2019.05.012 _zhttps://dx.doi.org/10.1016/j.rmed.2019.05.012
942			_cART _dArticle
999			_c4402 _d4402